EC Number   |
Application |
Reference |
|---|
   3.4.21.76 | analysis |
knowledge of the protonation states of the ionizable residues in an enzyme like PR3 is a prerequisite to an accurate description of its structure and mechanism |
709688 |
| 3.4.21.76 | diagnostics |
anti-neutrophil cytoplasmic antibodies with proteinase 3 specificity are a useful laboratory biomarker for the diagnosis of granulomatosis with polyangiitis, i.e.Wegener's granulomatosis |
731997 |
| 3.4.21.76 | drug development |
design of inhibitors aimed at neutralizing the cleavage activity of PR3 toward endogenous annexin 1 and hence suitable for development as novel anti-inflammatory therapeutics |
687618 |
| 3.4.21.76 | drug development |
either blocking the membrane presentation of PR3 or neutralizing the functions of its binding partners may generate novel therapeutic strategies for anti-neutrophil cytoplasmic autoantibodies-associated vasculitis |
707338 |
| 3.4.21.76 | drug development |
enzyme inhibitors may prove to be targets for the generation of agents in the treatment of neutrophilic inflammatory disease |
731482 |
| 3.4.21.76 | drug development |
enzyme Pr3 is a target for the generation of agents in the treatment of neutrophilic inflammatory disease |
752941 |
| 3.4.21.76 | drug development |
further exploration of the S' subsites of Pr 3 may lead to the identification of highly selective, reversible competitive inhibitors of Pr 3 using a functionalized surrogate scaffold embellished with appropriate recognition elements |
707736 |
| 3.4.21.76 | drug development |
optimized sequences, which allow close interaction with the extended active site of Pr3 for the development of peptide or pseudopeptide inhibitors that do not interfere with Pr3-related proteases |
687566 |
| 3.4.21.76 | drug development |
proteinase 3-inhibiting antibodies may play a role in autoimmune vasculitis and can be exploited as highly selective inhibitors |
732115 |
| 3.4.21.76 | drug development |
recombinant PR3 variants have a great potential to study individual anti-PR3 responses and will advance the development of new epitope-based therapeutics |
686188 |
